MX2011003535A - Composiciones de virus de herpes bovino-1, vacunas, y metodos. - Google Patents

Composiciones de virus de herpes bovino-1, vacunas, y metodos.

Info

Publication number
MX2011003535A
MX2011003535A MX2011003535A MX2011003535A MX2011003535A MX 2011003535 A MX2011003535 A MX 2011003535A MX 2011003535 A MX2011003535 A MX 2011003535A MX 2011003535 A MX2011003535 A MX 2011003535A MX 2011003535 A MX2011003535 A MX 2011003535A
Authority
MX
Mexico
Prior art keywords
vaccines
compositions
bhv
methods
cattle
Prior art date
Application number
MX2011003535A
Other languages
English (en)
Inventor
Gopinath Raju Seetharaman
Richard Harland
Lee David Ii Albee
Mayur Navnitbhai Patel
Benedikt B Kaufer
Nikolaus Osterrieder
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2011003535A publication Critical patent/MX2011003535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación se refiere en términos generales al tratamiento o a la prevención de enfermedades en el ganado. De una manera más particular, la invención se refiere a la producción y uso del virus de herpes bovino 1 (BHV-1) modificado, y a su uso en las composiciones y vacunas que protegen al ganado de la infección por el BHV-1, mientras que no suprimen la respuesta inmunológica en el huésped. En un ejemplo, la invención se refiere al uso del BHV-1 modificado, administrado con inmunógenos adicionales, ya sea a través de la co-administración y/o a través de la administración en las vacunas de combinación, y al uso de estas vacunas para proteger al ganado de las enfermedades. En un ejemplo, el uso del BHV-1 modificado en las composiciones administradas facilita una respuesta inmunitaria a, o contra, inmunógenos adicionales.
MX2011003535A 2008-10-03 2009-10-01 Composiciones de virus de herpes bovino-1, vacunas, y metodos. MX2011003535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19510208P 2008-10-03 2008-10-03
PCT/US2009/059196 WO2010039934A1 (en) 2008-10-03 2009-10-01 Bovine herpes virus -1 compositions, vaccines and methods

Publications (1)

Publication Number Publication Date
MX2011003535A true MX2011003535A (es) 2011-09-21

Family

ID=41354075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011003535A MX2011003535A (es) 2008-10-03 2009-10-01 Composiciones de virus de herpes bovino-1, vacunas, y metodos.

Country Status (12)

Country Link
US (1) US8637046B2 (es)
EP (1) EP2337582A1 (es)
JP (1) JP5723280B2 (es)
CN (1) CN102238961A (es)
AU (1) AU2009298490A1 (es)
BR (1) BRPI0920800A2 (es)
CA (1) CA2738664C (es)
CL (1) CL2011000742A1 (es)
CO (1) CO6361950A2 (es)
MX (1) MX2011003535A (es)
RU (1) RU2011117241A (es)
WO (1) WO2010039934A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877211B2 (en) * 2011-06-27 2014-11-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Bovine herpes virus vaccine with multiple mutations
CN104640991B (zh) * 2012-07-04 2017-09-19 昆士兰州农渔林业部 重组低毒力1型牛疱疹病毒(BoHV‑1)疫苗载体
CN105343877B (zh) * 2015-11-26 2019-03-01 中国兽医药品监察所 一种5基因缺失伪狂犬病重组病毒活疫苗及其制备方法
WO2017096267A1 (en) * 2015-12-03 2017-06-08 Chowdhury Shafiqul I Bovine herpesvirus type 1 (bohv-1) vector against bovine respiratory disease complex
AU2019239562A1 (en) * 2018-03-19 2020-08-13 Boehringer Ingelheim Vetmedica Gmbh New EHV with inactivated UL18 and/or UL8
CN113817027A (zh) * 2021-07-13 2021-12-21 中国农业科学院兰州畜牧与兽药研究所 一种牛疱疹病毒Ⅰ型gE蛋白胞外区的原核可溶性表达方法
CN114107230B (zh) * 2021-11-29 2023-08-11 东北农业大学 一种牛疱疹病毒1型ul41缺失毒株及其获取方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593873A (en) * 1986-01-27 1997-01-14 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
US6410033B1 (en) * 1987-07-27 2002-06-25 Syntro Corporation Recombinant infectious bovine rhinotracheitis virus
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
CA2496750C (en) 2002-08-26 2014-10-21 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
US20040185056A1 (en) 2003-01-03 2004-09-23 Board Of Regents, University Of Nebraska-Lincoln Vaccines containing bovine herpesvirus 1 attenuated by mutation in latency-related gene
GB0406389D0 (en) 2004-03-22 2004-04-21 Istituto Superiore Di Sanito Recombinant herpes simplex virus and uses therefor
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
ME01545B (me) 2006-01-26 2014-04-20 Zoetis Services Llc Preparati s novim glikolipidnim adjuvansom

Also Published As

Publication number Publication date
US8637046B2 (en) 2014-01-28
EP2337582A1 (en) 2011-06-29
AU2009298490A1 (en) 2010-04-08
CN102238961A (zh) 2011-11-09
JP2012504417A (ja) 2012-02-23
JP5723280B2 (ja) 2015-05-27
WO2010039934A1 (en) 2010-04-08
US20120034262A1 (en) 2012-02-09
CL2011000742A1 (es) 2011-10-14
BRPI0920800A2 (pt) 2020-08-11
CO6361950A2 (es) 2012-01-20
RU2011117241A (ru) 2012-11-10
CA2738664A1 (en) 2010-04-08
CA2738664C (en) 2017-10-31

Similar Documents

Publication Publication Date Title
MX2011003535A (es) Composiciones de virus de herpes bovino-1, vacunas, y metodos.
RS20100059A (en) RECOMBINANT KOI HERPESVIRUS (KHV) OR HERPESVIRUS 3 CYPRINID (CyHV-3) AND A DISEASE PREVENTION CAUSED WITH KHV / CyHV-3 IN CYPRINUS CARPIO CARPIO OR CYPRINUS CARPIO KOI
MX368897B (es) Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
MX2010003642A (es) Nanotecnologia de vacuna.
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MY171356A (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
WO2009156405A8 (en) Novel immunoadjuvant flagellin-based compounds and use thereof
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2010123569A3 (en) Immunonanotherapeutics providing a th1-biased response
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MY169275A (en) Method of immunization against the four serotypes of dengue
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
MX2009006178A (es) Vacuna contra salmonela.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
MX351380B (es) Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino.
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
EP2595643A4 (en) ANTIVIRAL PROPERTIES OF ALOEES AND TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
WO2013104995A3 (en) Compositions and methods for treating viral infections
MX2020011107A (es) Regimen de glicosidasa para el tratamiento de enfermedades infecciosas.
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.